FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/06/2024
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Rebecca Liebowitz Venable LLP
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Reagents for use in medical research and scientific research being biological analysis; proteins for use in the manufacture of pharmaceuticals and reagents; proteins in raw material form for use in medical research; cells, cell lines, and cell cultures, all being cells for clinical laboratory use, for use in the production of proteins for therapeutic use
Classe 5
Pharmaceutical and veterinary preparations and substances for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; biopharmaceutical preparations and substances for treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; chemical, biochemical and biological preparations for medical and veterinary purposes for the treatment of immune response disorders, genetic conditions, cancer, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases, infectious diseases and cardiovascular diseases; cells, cell lines, and cell cultures, all being cells for medical use, for use in the production of proteins for therapeutic use; reagents for medical use, namely, proteins being medical therapeutic reagents; therapeutic antibodies; vaccines
Classe 42
Scientific and technological services, namely, scientific research and design relating thereto in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; laboratory research services in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; medical and pharmacological research services; scientific research, namely, scientific analysis and testing being measurement of substances in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; scientific analysis and measurement of molecules and characteristics in the field of analytical sciences, biophysics, chemistry, biochemistry, biotechnology, molecular sciences and mass spectrometry; bioanalysis services; scientific imaging services; biochemical analysis; scientific research and development services; medical research and medical development services in the field of immunology, genetic conditions, oncology, immuno-oncology, ophthalmology, haematology, neurology, respiratory diseases, metabolic conditions, infectious diseases and cardiovascular diseases; pharmaceutical research and development services; biological research and analysis; biomedical research services; biotechnological research, namely, biotechnology scientific testing, in the biotechnical, biomedical and pharmaceutical fields; chemical research and analysis; research and development of new products for others in the biotechnical, biomedical and pharmaceutical fields; pharmaceutical research and development for the pharmaceutical industry; research and development of vaccines and medicines; scientific research and development services in the field of antibodies; scientific research and development services in the field of antibody technology; scientific research and development services in the field of immunology; medical laboratory services; research of pharmaceuticals; research relating to molecular sciences; research relating to pharmaceuticals; biopharmaceutical research, development and testing being product testing services; drug discovery services; product development, namely, drug development services; pharmaceutical drug development services; conducting early evaluations in the field of new pharmaceuticals; scientific research and development of molecules for therapeutic purposes; consultancy, advisory and information services in relation to all the aforesaid services
Histórico de despachos e eventos da marca no USPTO.
31 publicações encontradas
FINAL DECISION TRANSACTION PROCESSED BY IB
02/06/2024
FINAL DISPOSITION NOTICE SENT TO IB
10/05/2024
FINAL DISPOSITION PROCESSED
10/05/2024
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/05/2024
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/02/2024
REGISTERED-PRINCIPAL REGISTER
06/02/2024
NOTIFICATION PROCESSED BY IB
21/11/2023
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/11/2023
PUBLISHED FOR OPPOSITION
21/11/2023
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/11/2023
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/11/2023
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/11/2023
APPROVED FOR PUB - PRINCIPAL REGISTER
16/10/2023
EXAMINER'S AMENDMENT ENTERED
16/10/2023
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
16/10/2023
EXAMINERS AMENDMENT E-MAILED
16/10/2023
EXAMINERS AMENDMENT -WRITTEN
16/10/2023
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/10/2023
ASSIGNED TO EXAMINER
18/09/2023
TEAS/EMAIL CORRESPONDENCE ENTERED
20/07/2023
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/07/2023
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/07/2023
REFUSAL PROCESSED BY IB
24/05/2023
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
04/05/2023
REFUSAL PROCESSED BY MPU
04/05/2023
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
16/03/2023
NON-FINAL ACTION WRITTEN
15/03/2023
ASSIGNED TO EXAMINER
13/03/2023
APPLICATION FILING RECEIPT MAILED
18/10/2022
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/10/2022
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/10/2022
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.